

Application of 'Omics Technology to Infectious Diseases and the Human Microbiome

Karen Nelson
Marcus Jones

Historical...

- Genome of *Haemophilus influenzae* - 1995
- Reverse vaccinology - 2000
- Sargasso Sea Study - 2004
- First Human microbiome publication - 2006
- Diploid human genome - 2007
- Genome transplantation - 2007
- Global Ocean Survey, GOS - 2007
- Synthetic microbial genome - 2008
- >11,000 influenza genomes (75% of total worldwide and ongoing)
- Sequenced most major pathogens (e.g. TB, malaria, cholera, *T. parva*, *T. cruzi*)
- Vaccine development program – 2010
- Bacterial cell controlled by a synthetic chromosome – 2010

First Genome Sequenced 1995


25 thousand sequences

6.25×10^8 pairwise comparisons



DNA synthesis Makes “Impossible” Genetic Manipulations Doable in Real Time

- We can synthesize genes and chromosomes cheaply and rapidly
- Enormous potential for new health and industrial applications
 - Production of biofuels
 - Small molecule therapeutics
 - New vaccines, antibiotics
 - Therapeutic microbes
 - Chloroplasts as plant factories
- Understand basic biology



Metagenomics


- We are capable of sequencing and analyzing the genomes of culturable species
- These species are estimated to represent less than 1% of total microbial diversity

Culture dependent analysis:

Culture and obtain pure colonies
Complete genome sequencing of DNA
Organism has to be cultured in the laboratory

Culture-independent analysis

16S ribosomal RNA (rRNA) sequencing
Whole genome sequencing, assembly, annotation



- **Metagenomics:** sequence based analysis of complete microbial communities without need for culturing

Made possible by number of parallel developments:


- **Assembly and data analysis capabilities developed to being able to tease apart these large datasets**
- **Sequencing capabilities capable of achieving great depths of coverage at reduced cost**
- **Demonstrated proof of concept via Sargasso Sea study**
- **Global Ocean Sampling (GOS) largest protein dataset in existence**

Other “omics” technologies. Proteomics, metatranscriptomics, metabolomics

Changes in Sequencing Technologies



ABI 3730xl 1-2 Mb/day



**Illumina GA IIX
50 Gb/12day run**



**ABI SOLiD
100Gb/12 day run**



**454 GS FLX +
0.6Gb/23hr run**



**Illumina HiSeq 2000 (2500[†])
600 Gb/11day run**



**Ion Torrent
1Gb/2hr run**




Ion Proton[‡]

[†] *HiSeq 2500 upgrade: up to 120Gb/27 hour run (available now for \$50K)*

[‡] *Ion Proton: up to 100Gb/4 hour run (available at the end of 2012)*

Changes in genomics sciences

Sequence Production (Gbp)




| | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 |
|------------------------------|------|------|------|------|------|------|-------|
| # of Sequencers | 100 | 100 | 78 | 55 | 29 | 9 | 9 |
| FTE | 77 | 70 | 64 | 60 | 30 | 17 | 13 |
| Sequence data produced (Gbp) | 24 | 27 | 38 | 36 | 350 | 900 | 14000 |

Sargasso Sea study

- Venter and colleagues at the JCVI
- Generated 1,987,936 DNA reads
- Approximately 1,625 Mb of DNA
- 1.2 million new genes identified
- ~1,412 rRNA genes
- Estimated 1,800 species
- 12 complete genomes recovered
- Demonstration of the power of genomics



Global Ocean Sampling Expedition





Global Ocean Sampling and Analysis


Sampling and Sequencing



Tool Development



Data Analysis




GOS increases size and diversity of known protein families


(Yooseph et al, 2007 *PLoS Biol*)

GOS: prokaryotes, eukaryotes

Known: prokaryotes, eukaryotes




RuBisCO




Glutamine synthetase (type II)

Spin off “omics” studies transcriptomics – metabolomics

Metagenomic projects



Human Colon




Mucosal samples were obtained during colonoscopy from healthy-appearing sites within the six major subdivisions of the human colon: cecum
ascending colon
transverse colon
descending colon
sigmoid colon
rectum.

Fecal samples were collected from each subject 1 month following colonoscopy.

From 11,831 bacterial and 1524 archaeal 16S sequences, identified 395 phylotypes

Stomach



1,833 full-length 16S sequences

Described 128 16S rDNA phylotypes

Derived from 23 human subjects

Bik, E.M. et al. (2006) PNAS 103, 732-737

- First human metagenomic paper
- Investigated the gastrointestinal tract (via fecal samples) of two healthy adults
- 78 Mbp
- 2062 amplified 16S rDNA

RESEARCH ARTICLE

Metagenomic Analysis of the Human Distal Gut Microbiome

Steven R. Gill,^{1*} Mihai Pop,^{1†} Robert T. DeBoy,¹ Paul B. Eckburg,^{2,3,4} Peter J. Turnbaugh,⁵ Buck S. Samuel,⁵ Jeffrey I. Gordon,⁵ David A. Relman,^{2,3,4} Claire M. Fraser-Liggett,^{1,6} Karen E. Nelson¹

The human intestinal microbiota is composed of 10^{13} to 10^{14} microorganisms whose collective genome ("microbiome") contains at least 100 times as many genes as our own genome. We analyzed ~78 million base pairs of unique DNA sequence and 2062 polymerase chain reaction-amplified 16S ribosomal DNA sequences obtained from the fecal DNAs of two healthy adults. Using metabolic function analyses of identified genes, we compared our human genome with the average content of previously sequenced microbial genomes. Our microbiome has significantly enriched metabolism of glycans, amino acids, and xenobiotics; methanogenesis; and 2-methyl-*D*-erythritol 4-phosphate pathway-mediated biosynthesis of vitamins and isoprenoids. Thus, humans are superorganisms whose metabolism represents an amalgamation of microbial and human attributes.

Our body surfaces are home to microbial communities whose aggregate ≥ 100 times as many genes as our 2.85-billion base pair (bp) human genome (*1*). Therefore, a

of single organisms, recent reports from Venter *et al.* (*9*) and Baker *et al.* (*10*) have demonstrated the utility of this approach for studying mixed microbial communities. Variations in the relative abundance of each member of the microbial community and their respective genome sizes determine the final depth of sequence coverage for any organism at a particular level of sequencing. This means that the genome sequences of abundant species will be well represented in a set of random shotgun reads, whereas lower abundance species may be represented by a small number of sequences. In fact, the size and depth of coverage (computed as the ratio between the total length of the reads placed into contigs and the total size of the contigs) of genome assemblies generated from a metagenomics project can provide information on relative species abundance.

A total of 65,059 and 74,462 high-quality sequence reads were generated from random DNA libraries created with fecal specimens of two healthy humans (subjects 7 and 8). These two subjects, ages 28 and 37, female and male, respectively, had not used antibiotics or any

Gill et al, *Science* 200

Human Microbiome Metagenomics, Health and Disease

Human Microbiome

$\sim 10^{12}$ Human cells

$\sim 10^{13}$ Bacterial cells



>600 oral bacterial species

Human Microbiome

- **Collective of the human microbiome exceeds the number of human cells by at least an order of magnitude.**
- **Many of these microbial interactions endow or enhance human physiology including processes related to development, nutrition, immunity and resistance to pathogens.**
- **The majority of the human microbiome remains unknown.**
- **Many relationships between the human host and microbiome remain to be determined**



image courtesy of the NIH HMP website
<http://nihroadmap.nih.gov/hmp/>

The Human Microbiome


Significant role: Example in the Gastrointestinal tract

- They foster development of the mucosal wall.
- The development and maturation of the immune system is dependent on the presence of some members of the intestinal microbiota. Link to human health and disease.
- Essential for the metabolism of certain compounds as well as xenobiotics.
- Protection against epithelial cell injury.
- Regulation of host fat storage.
- Stimulation of intestinal angiogenesis.



Microbiota are acquired *anew* each generation.

2) Microbial succession over ~1-2 yrs.

Dominguez-Bello et al. (2010).




1) Infants obtain microbes from mother or environment.



3) Microbiome becomes "adult-like" in ~1-2 yrs.

NIH Roadmap Human Microbiome Project

- **Budget > \$175 million 2007-2013**
- **Goal: Characterize the microbes that inhabit the human body and examine whether changes in the microbiome can be related to health and disease**
- **Feasibility project designed to determine the value of microbial metagenomics to biomedical research**
- **Community Resource Project-generate reagents and data sets; rapidly placed in public domain**
- **Continuous Scientific Community Input
External Scientific Advisory Group, Workshops.**
- <http://nihroadmap.nih.gov/hmp>
- <http://www.human-microbiome.org/#>



“Healthy Cohort” Body Sites

Oral

- Saliva
- Tongue dorsum
- Hard palate
- Buccal mucosa
- Keratinized (attached) gingiva
- Palatine tonsils
- Throat
- Supragingival plaque
- Subgingival plaque

Skin

- Retroauricular crease, both ears (2)
- Antecubital fossa (inner elbow), both arms (2)

Nasal


- Anterior right and left nares (pooled)


Gut

- Stool

Vaginal


- Posterior fornix, vagina
- Midpoint, vagina
- Vaginal introitus





Supplementary Figure 8. Phylum abundances per body site. For each of the body sites studied by both 16S rRNA gene sequencing (A) and whole-genome shotgun sequencing (B) the five most abundant phyla are shown. The small remaining fraction of the data is collapsed and labeled as other phyla (grey).

In adults, each part of the body supports a distinct microbial community.



With no apparent relationship with gender, age, weight, ethnicity or race.


J. Craig Venter™

HMP estimates for global microbiome:

~ 10,000 microbial species


~ 8 million microbial genes

Sub-body sites have distinct communities



| | | |
|------|---|----------------------|
| Soft | 1 | Cheek |
| | 2 | Palate |
| | 3 | Gums |
| | 4 | Tonsils |
| | 5 | Saliva |
| | 6 | Subgingival Plaque |
| | 7 | Supragingival Plaque |
| Hard | 8 | Throat |
| | 9 | Tongue |

1 2 3 4 5 6 7 8 9





Slide courtesy of HMP Consortium
and Bruce Birren, Broad Institute

- **Reference Strains:** Generate complete genomes from > 3000 prokaryotes.
- Build our understanding of those recognized through 16S profiles
- Provide for interpretation of metagenomics and other “omics” data
- Sequence reference phage, viruses and eukaryotes

A Catalog of Reference Genomes from the Human Microbiome

178 genomes
 ~550,000 genes
*Nelson et al.,
 Science*
 May 21, 2010





Reference Genomes of the Human Microbiome Project

In order to facilitate the phylogenetic and functional analysis of the metagenomic sequences produced from human body sites, the HMP plans to sequence, or collect from publicly available sources, a total of 1000 reference genomes. The organisms included in this collection have all been isolated from a human body site. The information gained from the Reference Genomes will allow 16S RNA sequences and metagenomic sequence from uncharacterized microbiome organisms to be grouped phylogenetically with related organisms from the reference set providing information about the taxonomy of the unknown strains. Likewise, functional characterization of proteins in the reference organisms will aid in the functional annotation of related proteins contained in the sequence fragments derived from metagenomic samples.

Choosing Reference Organisms:

The HMP has developed a detailed set of guidelines for inclusion of a strain in the reference genome group. If you have suggestions for additional strains to include on the list or if you have a strain that you would like to contribute please use our feedback form to let us know.

- ▶ [Guidelines for inclusion of a strain](#)
- ▶ [Feedback form](#) - help us by recommending strains to include in the HMP reference genome collection
- ▶ [Current breakdown of strains according to body site](#)
- ▶ Phylogenetic Analysis - Below are phylogenetic trees of HMP organisms in the context of a wide sampling of sequenced and/or culturable bacteria:
 - ▶ [All HMP reference genomes](#)
 - ▶ [Reference genomes isolated from airways](#)
 - ▶ [Reference genomes isolated from the gastrointestinal tract](#)
 - ▶ [Reference genomes isolated from the oral cavity](#)
 - ▶ [Reference genomes isolated from the skin](#)
 - ▶ [Reference genomes isolated from the vagina](#)

HMP Catalog

For a full list of the HMP reference genomes please visit the [HMP Project Catalog](#) where you can search for strains by many features and characteristics, including body site and taxonomy. The collection of strains in the HMP Project Catalog represents projects at all stages including those that are planned (project status "targeted") as well as those that have reached completion (project status "complete"). Also included in the set are strains that are being sequenced by members of the International Human Microbiome Consortium (link to further down section of page). More information on this effort can be found further down this page.

Most of the HMP Reference Genomes will be sequenced only to the "standard draft" stage, a minimum standard for a draft genome that has been established by the HMP sequencing centers. Draft genome sequence does not include every base of the genome, rather they are assemblies of several large contiguous pieces of sequence (contigs) with subsequent gaps in sequence knowledge. About 15% of the reference strains will be taken closer to a "finished" or fully complete state. There are several finishing levels that genomes can be taken to, each with an associated cost. The same guidelines mentioned above for choosing which strains to include on the list are applied to decide which of the strains should be promoted to a higher state of finishing. A standardized set of Finishing Categories is currently under development by a multi-center, international group of researchers. Once finalized, they will be posted on this site and each strain will be assigned to one of the categories.

The Human Microbiome: Altering the future of medicine


- Microbiome influenced by many factors including environment and host genetics
 - Complex bio-feedback mechanism: host <-> microbiome
- This population can be studied and altered to benefit the host
 - Normal flora of healthy individuals can potentially be mined to identify new probiotics
 - Population changes/shifts can be used as indicators of deterioration/improvement of health
 - Can be used for disease surveillance
- Need for integration of multiple “omics” approaches to understand the complexity of the microbiome and its broader implications

Disease related microbiome studies at JCVI

- **Progression of esophageal cancer (NYU)**
- **Bacterial vaginosis and pre-term delivery (Illinois/Mayo; NIAID)**
- **Nasopharynx microbiome and vaccination in children (Gates)**
- **Skin microbiome, acne and psoriasis (NYU)**
- **Oral diseases including periodontitis (NYU)**
- **Colon cancer (Howard University)**
- **Type 1 Diabetes pilot (TEDDY)**

Can we use as a biomarker for:

- Development of new predictive biomarkers so that preventive strategies based on pre- and probiotics can be developed.
- New therapeutic strategies
- Increase our understanding of the etiologies of complex diseases and health



Integrated "omics" approaches

NIDDK funded - Type 1 Diabetes Study

Gut Microbiome/Virome

Urinary Proteome

Urinary Metabolome

Viral-Microbial specific
Biosignatures

Protein patterns

Metabolite analysis

Compare and correlate gut microbiome, proteomic and metabolomic datasets –
On host side - HLA genotype, islet autoantibody status and Type 1 Diabetes status

Identification of panel of Biomarkers Candidates

Still need:

- Technology development
- Informatics and data handling
- Education
- Well defined studies


Transcriptomic and Proteomic Analyses of the Microbiome and Infectious Diseases

“Omics” Technologies


- Metagenomic Analysis
- **Transcriptomics**
- **Proteomics**
- Glycomics
- Lipodomics
- Metabolomics

What is Transcriptomics?


Transcriptomics Technologies





Characterization of *in vitro* Samples




SOS




Environmental Stress



Effect of levofloxacin on *B. anthracis* γ -polymerase




SOS response in *B. anthracis*




"DNA-damage-inducible protein P, putative"
LexA repressor
"recA protein, group I intron-containing"
"excinuclease ABC, A subunit"
"excinuclease ABC, B subunit"
"excinuclease ABC, C subunit"

in vitro Gene Expression


RNA
purification




cDNA
synthesis



Microarray
Hybridizations



Data analysis



Genome Sequencing

gDNA



454 Sequencing




Newbler
assembly

```
AGTATTTCTT ATGAACGAGT TAGACGGCAT  
GGAATAATCT ATGAACGC AA TAATTATTGA  
ATAACTTTCT ATGAAAGTAA ACTTAATCT  
CGAGGCAAAA ATGAGCAAAG TCAGACTCGC  
GGAAGACCAT ATGCTTGACG CTCAAACCAT  
SAAAGCCGT GTGATTTGTT AACGACCCGT  
ATATGTTTCA ATGTTTTTCA AAAAGAACCT  
ATTTTACC ACC ATGCTCACCG TTAAGCAGAT  
GAATAAATC ATGCTACCAT CTATTTCAAT  
AAGGTGAGAT ATGCACTCTC AAATCTGGGT  
AGAGGACCC ATGCACTCGA TGCTGAACAT  
AGAATTACCT ATGAACGC AA TAATAACAT
```



3' qPCR
confirmation




Mapping Promoters: Chip-chip Analysis of *in vitro/ ex vivo* Samples


Cross-link protein to DNA




Sonicate to fragment to DNA




Immunoprecipitate




Purify and label DNA




Hybridize to microarray




(+) strand -- Chromosome



(-) strand -- Chromosome




Log (IB/IA) -- Chromosome



RpoE
Binding
Site Oligos




RNASeq Data





Linezolid Lineage Clinical Isolates

| <u>locus</u> | <u>start</u> | <u>end</u> | <u>symbol</u> | <u>WT</u> | <u>SNP</u> | <u>3577</u> | <u>5612</u> | <u>5892</u> | <u>7210</u> | <u>function</u> |
|--------------|--------------|------------|---------------|-----------|------------|-------------|-------------|-------------|-------------|--|
| SA2212 | 2483696 | 2482581 | N/A | G | C | negative | positive | positive | positive | hypothetical protein |
| SA1577 | 1815520 | 1808960 | N/A | T | G | negative | positive | positive | positive | hypothetical protein |
| SA1118 | 1268775 | 1270448 | N/A | T | C | negative | positive | positive | positive | hypothetical protein |
| SA1924 | 2173700 | 2172273 | N/A | A | G | negative | positive | positive | positive | hypothetical protein |
| SA1669 | 1906904 | 1905519 | fumC | A | G | negative | positive | positive | positive | fumarate hydratase |
| SA0500 | 579620 | 583171 | rpoB | T | A | negative | negative | positive | positive | DNA-directed RNA polymerase subunit beta |
| SA0264 | 318934 | 319926 | N/A | C | T | negative | negative | positive | positive | hypothetical protein |


Two-step Resistance



qRT-PCR Validation using Roche 480 LC



Characterization of Pathogen Gene Expression During Infection



Hypothetical genes differentially expressed *in vivo*






Figure 1




APOPTOSIS

Extrinsic Pathway

Death Ligand




Adaptor






Cytokine-cytokine receptor interaction


Survival Factors



Ca²⁺-induced Cell Death Pathways



Role Category Analysis



What is Proteomics?

Additional Public Health Concerns

- UTIs are the most common cause of hospital-acquired infections accounting for approximately 40% of the total
- Many of these UTIs are caused by the ESKAPE pathogens. There is an increasing shortage of effective antibiotics againsts pathogens with multiple resistances
 - Enterococcus faecium
 - Staphylococcus aureus
 - Klebsiella pneumoniae
 - Acenitobacter baumannii
 - Pseudomonas aeruginosa
 - Enterobacter species
- Carbapeneme (Kp, Ec); MDR (Pa); penicillins and vancomycin (Ef, Sa)
- Large number of immune-compromised patients: HIV/AIDS, transplant and cancer patients

More informative Methods for UTI and ASB Diagnosis ?

- Vaginal and urinary tract microbiome profiling (sensitive detection of protective bacteria, ESKAPE pathogens, anaerobes missed in urine cultures): metagenomics
- Protein profiling to identify the bacteria and survey antimicrobial and immune responses: proteomics

Fouts et al., J Transl Medicine (2012) 10, 174:



“Integrated next generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury”

Proteomics: Analysis Stages


Peptide separation




Sample acquisition



Electrospray



LC-MS/MS



Mascot data analysis

| | | | | | |
|-----|-------------------|-------------------|-------------------|-------------------|--------------------|
| 1 | MARTPIARY | RNIGISAMID | AGKTTTTERI | LFYTGVMHKI | GEVHDGAATH |
| 51 | DWMEQEERG | ITITSAATTA | FWSGMAKQYE | PHRINIIDTP | GHVDFTIEVE |
| 101 | RSMRVLGDGAV | MVYCAVGGVQ | PQSETVWRQA | NKYKVPRIAF | VNKMDR MGAN |
| 151 | FLKVVNQIKT | RLGANPVPLQ | LAIGAEHFT | GVVDLVKMKK | INWNDADQGV |
| 201 | TFEYEDIPAD | MVELANEWHQ | NLIESAAEAS | EELNEKYLGG | EELTEAEIKG |
| 251 | ALRQRVLNNE | IILVTCGSF | KNKGVMQLD | AVIDYLPSPV | DVPAINGILD |
| 301 | DGKDTPAERH | ASDDEPFSAL | AFKIATDPFV | GHLTFFRVYS | GVVNSGDTVL |
| 351 | NSVKAARERF | GRIVQHANK | REEIKEVRAG | DIAAAIGLKD | VTTGDTLCPD |
| 401 | DAPIILERME | FPEPVISIAV | EPKTKADQEK | MGLALGRLAK | EDPSFRVWTD |
| 451 | EESNQTIAG | NGELHLDIIV | DRMKREFNVE | ANVGKPOVAY | RETIRQVTD |
| 501 | VEGKHAKQSG | GRGQYGHVVI | DMYPLEPGSN | PKGVEFINDI | RGGVIPGEYI |
| 551 | PAVDKGIQEQ | LKAGPLAGYP | VVDHGIRLHF | GSYHDVDSSE | LAFK LAASIA |
| 601 | FKEGFKKAKP | VLLEPDMVE | VETPENTGD | VIGDLSRRRG | MLK GQESEVT |
| 651 | GVKIHAEVPL | SEMFGYATQL | RSLTKGRASY | TMEFLKYDEA | PSNVAQAVIE |

Quantitative methods

- Annexin A1 n=14 Tax=Eutheria RepID=ANXA1_HUMAN
- Alkyl hydroperoxide reductase subunit C [Klebsiella pneumoniae 342]

Database searches

- human protein sequence database UniRef90
- uropathogenic *E. coli*
- *Klebsiella pneumoniae*
- *Proteus mirabilis*
- *Pseudomonas aeruginosa*
- *Enterococcus faecalis*
- *Enterobacter hormachei*
- *Lactobacillus jensenii*
- *Morganella morganii*
- *Corynebacterium urealyticum*
- *Peptoniphilus asaccharolyticus*
- *Streptococcus pneumoniae*
- *Prevotella intermedia*
- *Staphylococcus epidermidis*

The database search space comprises ~80,000 distinct proteins

Patent application: Pieper et al., January 2013

Acknowledgements

- All JCVI faculty, staff and collaborators
- Funding Agencies: NIH
 - NIAID
 - Genome Sequencing Center (**NIH-HHSN272200900007C**)
 - System Biology for Enteropathogens (**NIH-HHSN27220070058C**)
 - Pathogen Functional Genomics Resource Center (**N01-AI-15447**)
 - NIDCR
 - NIDDK